Chinese Drug Regulator Accepts Marketing Application of Humanwell Healthcare's Unit for Pregabalin Tablets
MT Newswires Live
Sep 01
China's National Medical Products Administration accepted the drug registration and marketing authorization application of Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, for pregabalin extended-release tablets, according to a Shanghai bourse filing on Tuesday.
The drug is used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.
The pharmaceutical company invested 62 million yuan into the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.